Catalyst Pharmaceutical
CPRX
50 hedge funds and large institutions have $49.3M invested in Catalyst Pharmaceutical in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 10 closing their positions.
97% more capital invested
Capital invested by funds: $25M → $49.3M (+$24.3M)
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
1.76% more ownership
Funds ownership: 28.74% → 30.5% (+1.8%)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
7% less funds holding
Funds holding: 54 → 50 (-4)
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$3.39M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$764K |
| 3 |
BlackRock
New York
|
+$704K |
| 4 |
Renaissance Technologies
New York
|
+$487K |
| 5 |
DMK
David M. Knott
|
+$362K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KCM
51
Kingdon Capital Management
New York
| – | -$794K | -756,311 | Closed |
|
52
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$63K | -59,541 | Closed |
|
|
VKH
53
Virtu KCG Holdings
New York
| – | -$57K | -54,200 | Closed |
|
|
PAG
54
Private Advisor Group
Morristown,
New Jersey
| – | -$28K | -24,500 | Closed |
|
|
HSA
55
HBK Sorce Advisory
Erie,
Pennsylvania
| – | -$26.9K | -21,109 | Closed |
|
56
Squarepoint
New York
| – | -$19K | -18,000 | Closed |
|
57
D.E. Shaw & Co
New York
| – | -$13K | -12,651 | Closed |
|
|
CCM
58
Compton Capital Management
Providence,
Rhode Island
| – | -$11K | -10,000 | Closed |
|
59
Walleye Trading
New York
| – | -$2K | -1,900 | Closed |
|
60
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | -1,000 | Closed |
|
CPRX Hedge Fund Activity: Q1 2017 in Review
50 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2017, worth a combined $49.3M — up 97% from $25M a quarter earlier.
Fund positioning in CPRX was balanced in Q1 2017: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 10 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $3.39M. The largest seller was Point72 Asset Management, cutting an estimated $1.78M.
- 50 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2017, down from 54 in Q4 2016.
- Funds reported $49.3M of Catalyst Pharmaceutical stock for Q1 2017, up 97% quarter-over-quarter.
- 10 funds opened new Catalyst Pharmaceutical positions in Q1 2017 and 10 closed out, a net change of 0 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2017 was Avoro Capital Advisors, an estimated $3.39M added.
- The largest Catalyst Pharmaceutical seller in Q1 2017 was Point72 Asset Management, an estimated $1.78M sold.
Based on aggregated 13F filings for Q1 2017.